A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more than 40 years, but says when so called GLP-1 drugs made from semaglutide ...

Weight loss is a common goal for many, and while diet and exercise remain essential, some turn to medications like Mounjaro ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...